Last updated: April 25, 2026
Cipla Ltd. v. Boehringer Ingelheim Pharmaceuticals Inc., 1:22-cv-00300: Litigation Snapshot and Patent Case Analysis
What is the case and what stage is it in?
Cipla Ltd. v. Boehringer Ingelheim Pharmaceuticals Inc. is docketed as 1:22-cv-00300 in the US District Court for the District of Delaware. The parties’ names appear as Cipla Ltd. (plaintiff) vs. Boehringer Ingelheim Pharmaceuticals Inc. (defendant) on the case caption.
The case is a patent dispute connected to Cipla’s market entry and Boehringer Ingelheim’s patent estate for its US pharmaceutical product(s). This is consistent with the case’s linkage to the US FDA approval pathway typically governed by Hatch-Waxman procedures, where the filing posture is commonly an infringement challenge and the docket tracks the asserted US patents, Orange Book listings, and FDA-related trigger dates.
Forum: US District Court, District of Delaware
Case number: 1:22-cv-00300
Parties: Cipla Ltd. v. Boehringer Ingelheim Pharmaceuticals Inc.
What patents and products are at issue?
The question turns on what Boehringer Ingelheim listed in the Orange Book for the relevant NDA/ANDA and what Cipla challenged or alleged in its complaint. The docket summary required for a complete and accurate analysis depends on the exact asserted US patents (numbers), the product and dosage form tied to those patents, and the claims and invalidity theories pled by Cipla.
At present, the information available in the prompt does not include:
- the asserted patent numbers
- the FDA application (NDA/ANDA) and product name
- the case filings listing the patents (e.g., complaint, infringement contentions, answer, claim construction order)
- the procedural timeline (Rule 16 scheduling, Markman, summary judgment, trial or settlement terms)
Given the “no speculation” constraint for this task, a precise listing of the patents and the product scope cannot be produced from the provided input.
What are the likely legal theories (and what to verify in the record)?
In Hatch-Waxman disputes in Delaware, litigation frameworks typically include:
- Infringement allegations against Cipla’s proposed product
- Invalidity defenses (anticipation, obviousness, lack of written description/enablement, indefiniteness where relevant)
- Non-infringement based on claim construction and product characterization
- Equitable defenses where pled (e.g., prosecution history estoppel or inequitable conduct, depending on the asserted patent family)
A complete analysis requires reading the operative complaint and any infringement contentions or claim charts to determine:
- whether Boehringer Ingelheim asserted method, composition, formulation, or use claims
- whether Cipla’s invalidity theories target specific prior art references and which claim elements they address
- whether the parties contest priority, claim construction scope, or design-around boundaries
No such record detail is included in the provided prompt; therefore, this section cannot be completed without generating unverifiable assertions.
What procedural milestones matter for an investment and R&D view?
For decision-making, the milestones with the highest downstream effect are:
- Markman/claim construction outcomes (can reshape infringement and invalidity)
- Daubert/experts rulings affecting technical credibility and case posture
- Summary judgment on key issues (often non-infringement or invalidity)
- Stipulated judgment or consent judgment tied to FDA approval timing
- Permanent injunction scope or carve-outs if a settlement occurs
The prompt does not include the procedural history (orders, claim construction dates, dispositive rulings, settlement docket entries). Without those, any milestone analysis would be non-factual.
How does this case typically impact Cipla’s US launch strategy and Boehringer’s exclusivity?
In these disputes, outcomes directly shape:
- whether Cipla can launch at-risk before the asserted patent expiry
- whether launch is blocked until a design-around or non-infringement position holds
- whether a settlement triggers early entry at a defined date or under defined labeling/product constraints
The business mechanism is usually governed by:
- injunction timing
- trigger dates linked to patent expiry and FDA approval
- entry terms (date, labeling, regulatory contingencies)
However, the exact terms for this matter are not present in the provided input. A factual launch impact statement requires at least the asserted patent expiry, whether a consent judgment exists, and any triggered entry date in the docket or orders.
What does the case imply about Boehringer’s patent durability?
Patent durability in this context is measured by:
- claim survival at claim construction and dispositive stages
- invalidity vulnerability relative to prior art and written description/enablement strength
- whether the asserted patents are in a family with staggered expiry (a key driver of settlement leverage)
A credible assessment needs:
- the asserted patent list
- the claim focus and asserted claim numbers
- known prior art and how the court handled it
None of that detail is available from the prompt.
Key Takeaways
- Case identity is clear: Cipla Ltd. v. Boehringer Ingelheim Pharmaceuticals Inc., 1:22-cv-00300, in the District of Delaware.
- A complete litigation and patent analysis is not possible from the provided information because the prompt does not include the asserted patent numbers, product scope, operative allegations, or procedural orders.
- Any attempt to list asserted patents, infringement/invalidity theories, claim construction outcomes, or launch impact would require docket record content that is not included here.
FAQs
1) What court and case number is this?
US District Court, District of Delaware, 1:22-cv-00300.
2) Who are the parties?
Cipla Ltd. and Boehringer Ingelheim Pharmaceuticals Inc.
3) Is this a Hatch-Waxman dispute?
The case posture is consistent with patent litigation tied to FDA approval pathways; however, the specific NDA/ANDA and asserted patents are not provided in the prompt.
4) What would determine the outcome in this type of case?
Claim construction, infringement mapping to Cipla’s proposed product, and invalidity theories against the asserted patent claims.
5) What are the business signals an investor would track in this docket?
Claim construction orders, summary judgment rulings, any consent judgment or settlement entry terms, and the resulting launch timing relative to patent expiry.
References
[1] US District Court for the District of Delaware. Cipla Ltd. v. Boehringer Ingelheim Pharmaceuticals Inc., Case No. 1:22-cv-00300 (case docket/caption).
